AstraZeneca halts late-stage trial of volrustomig in metastatic lung cancer
AstraZeneca said it is stopping a late-stage study of its experimental drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer. The company made the decision after a recommendation from an independent data monitoring committee.
The move adds to a string of recent setbacks for AstraZeneca and has intensified scrutiny of the firm’s development pipeline among analysts and investors.
In the same newsletter, Sandoz announced it will pay up to $77 million upfront to Shanghai Henlius Biotech for the rights to three biosimilar products, highlighting continued activity in the biosimilar market despite the AstraZeneca trial halt.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that